|
시장보고서
상품코드
2102152
위장관기질종양(GIST) 시장 규모, 점유율, 성장 분석 : 치료법별, 약물별, 병기별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Gastrointestinal Stromal Tumor Market Size, Share, and Growth Analysis, By Treatment Type, By Drug Type, By Disease Stage, By Route of Administration, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 위장 간질종양(GIST) 시장 규모는 2024년에 13억 8,000만 달러로 평가되었으며, 2025년 14억 7,000만 달러에서 2033년까지 23억 8,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 6.2%로 성장할 것으로 전망됩니다.
세계 위장관기질종양(GIST) 시장은 주로 1차 치료에 대한 내성을 효과적으로 극복하는 차세대 티로신 키나제 억제제에 대한 수요 증가에 힘입어 견조한 성장을 보이고 있습니다. 기존 치료를 받고 있는 환자들에게 내성이 발생함에 따라 2차 치료제로의 전환이 두드러지게 나타나고 있으며, 이에 따라 표적화된 돌연변이 특이적 치료법 개발을 위한 제약 업계의 혁신이 활성화되고 있습니다. 병용요법의 도입으로 무재발 생존율이 대폭 향상됨에 따라, 조달 및 재고 확충에 대한 투자가 증가하고 있습니다. 또한, 환자 계층화를 위한 동반진단, 복약 순응도를 모니터링하기 위한 원격의료, 시장 내 입지를 확대하기 위한 전략적 제휴에서도 중요한 비즈니스 기회가 발견되고 있습니다. GIST 진단 건수의 급증과 맞춤형 치료를 위한 분자 프로파일링의 발전은 시장을 주도하는 중요한 동향이며, 기존의 외과적 치료에서 표적 치료로의 전환을 촉진하고 있습니다.
세계 위장관기질종양(GIST) 시장의 성장요인
조기 진단에 대한 관심이 높아짐에 따라, 의료진은 위장관기질종양을 더 이른 단계에서 식별할 수 있게 되었으며, 그 결과 근치적 치료의 혜택을 받을 수 있는 환자의 범위가 확대되고 있습니다. 이러한 적극적인 접근 방식 덕분에 표적 치료의 신속한 시작이 가능해져 임상 결과가 개선될 뿐만 아니라, 임상의들이 승인된 치료 옵션을 활용하도록 동기를 부여하고 있습니다. 진단 지침에 대한 인식이 높아짐에 따라, 의료 종사자들은 분자 검사를 표준 진료에 점점 더 많이 도입하고 있으며, 이는 승인된 의약품에 대한 지속적인 수요를 뒷받침하여 시장 성장에 기여하고 있습니다. 나아가 이러한 추세는 제약 기업들이 이러한 진단 및 치료 전략의 지속적인 도입을 촉진하는 교육 프로그램을 실시하도록 유도하고 있습니다.
세계 위장관기질종양 시장의 제약요인
새로운 치료법에 수반되는 높은 비용은 위장관기질종양 치료 시장의 성장에 있어 큰 과제가 되고 있습니다. 가격 급등은 특히 환급 정책이 엄격하거나 보험 적용 범위가 불충분한 지역에서 환자의 접근성을 제한하고 있습니다. 의료비 지급 기관은 임상적 이점보다 비용 효율성을 우선시하는 경우가 많아, 그 결과 처방약 목록이 제한되고 처방량이 감소하고 있습니다. 또한, 의료 기관이 직면한 재정적 압박으로 인해 새로운 치료법의 도입이 지연되는 경우가 빈번하며, 임상의들은 더 오래되고 저렴한 대안에 의존할 수밖에 없는 실정입니다. 그 결과, 혁신적인 치료법이 가져다주는 잠재적인 치료상의 이점에도 불구하고, 이러한 재정적 장벽이 시장 전체의 수요를 저해하고 있습니다.
세계 위장관기질종양(GIST) 시장 동향
분자 프로파일링의 통합이 치료법 선택에 필수적인 요소로 자리 잡으면서, 전 세계 위장관기질종양(GIST) 시장에서는 정밀 종양학으로의 뚜렷한 전환이 진행되고 있습니다. 임상의들은 개별 유전자 프로파일에 맞춘 표적 억제제를 점점 더 많이 활용하고 있으며, 이에 따라 제약사들은 기존의 티로신 키나제 억제제에 국한되지 않는 파이프라인 다각화를 추진하고 있습니다. 이러한 추세는 진단 기업과의 전략적 제휴를 촉진하고, 동반진단 및 보험 적용 대상인 혁신적인 치료 패키지의 개발을 뒷받침하고 있습니다. 맞춤형 치료법이 환자의 예후를 개선하고 시장 내 보급을 촉진함에 따라, 전 세계 대학 병원 및 지역 의료 기관의 상황은 급속히 변화하고 있으며, 맞춤형 암 치료에 대한 노력이 더욱 강화되고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 위장관기질종양(GIST) 시장 규모 : 치료 유형별
세계의 위장관기질종양(GIST) 시장 규모 : 약물 유형별
세계의 위장관기질종양(GIST) 시장 규모 : 질환 스테이지별
세계의 위장관기질종양(GIST) 시장 규모 : 투여 경로별
세계의 위장관기질종양(GIST) 시장 규모 : 유통 채널별
세계의 위장관기질종양(GIST) 시장 규모 : 최종사용자별
세계의 위장관기질종양(GIST) 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.08.03Global Gastrointestinal Stromal Tumor Market size was valued at USD 1.38 Billion in 2024 and is poised to grow from USD 1.47 Billion in 2025 to USD 2.38 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).
The global gastrointestinal stromal tumor (GIST) market is experiencing robust growth, primarily fueled by the rising demand for next-generation tyrosine kinase inhibitors that effectively address resistance to first-line treatments. As patients on conventional therapies develop resistance, there is a notable shift towards second-line drugs, which has invigorated pharmaceutical innovation in developing targeted, mutation-specific therapies. The integration of combination regimens has significantly enhanced progression-free survival rates, prompting increased investment in procurement and inventory expansion. Key opportunities also lie in companion diagnostics for patient stratification, telemedicine for monitoring adherence, and strategic partnerships aimed at expanding market presence. The surge in GIST diagnoses and advancements in molecular profiling for personalized treatments are pivotal trends propelling the market forward, facilitating a transition towards targeted therapies over traditional surgical options.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastrointestinal Stromal Tumor market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Gastrointestinal Stromal Tumor Market Segments Analysis
Global gastrointestinal stromal tumor market is segmented by treatment type, drug type, disease stage, route of administration, distribution channel, end user and region. Based on treatment type, the market is segmented into targeted therapy, chemotherapy, immunotherapy, surgery, radiation therapy and others. Based on drug type, the market is segmented into tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, cytotoxic chemotherapy agents and others. Based on disease stage, the market is segmented into localized gastrointestinal stromal tumor (GIST), locally advanced gastrointestinal stromal tumor (GIST), metastatic gastrointestinal stromal tumor (GIST) and recurrent gastrointestinal stromal tumor (GIST). Based on route of administration, the market is segmented into oral and injectable. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, specialty cancer centers, ambulatory surgical centers and academic & research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Gastrointestinal Stromal Tumor Market
The growing focus on early diagnosis is enabling healthcare professionals to identify gastrointestinal stromal tumors at earlier stages, thus broadening the range of patients who can benefit from curative treatments. This proactive approach facilitates the prompt initiation of targeted therapies, enhancing clinical outcomes and motivating clinicians to utilize approved treatment options. As awareness of diagnostic guidelines rises, healthcare providers are increasingly incorporating molecular testing into their standard practices, which fuels persistent demand for approved medications and contributes to market growth. In turn, this trend encourages pharmaceutical companies to implement educational initiatives that promote the ongoing adoption of these diagnostic and treatment strategies.
Restraints in the Global Gastrointestinal Stromal Tumor Market
The high cost associated with new therapies presents a significant challenge to the growth of the gastrointestinal stromal tumor treatment market. Elevated prices restrict patient access, particularly in regions with stringent reimbursement policies or insufficient insurance coverage. Healthcare payers often prioritize cost-effectiveness over clinical benefits, leading to restrictive formularies that diminish prescription volumes. Additionally, financial pressures faced by healthcare institutions frequently result in delays in adopting newer treatments, causing clinicians to rely on older, more affordable options. Consequently, these financial barriers hinder overall market demand, despite the potential therapeutic advantages offered by innovative treatments.
Market Trends of the Global Gastrointestinal Stromal Tumor Market
The Global Gastrointestinal Stromal Tumor (GIST) market is experiencing a notable shift towards precision oncology, as the integration of molecular profiling becomes integral to therapy selection. Clinicians are increasingly utilizing targeted inhibitors tailored to individual genetic profiles, prompting pharmaceutical companies to diversify their pipelines beyond conventional tyrosine kinase inhibitors. This trend fosters strategic partnerships with diagnostic firms, enhancing the development of companion diagnostics and innovative treatment bundles that are eligible for reimbursement. As personalized regimens improve patient outcomes and drive market adoption, the landscape is evolving rapidly across academic and community healthcare settings worldwide, reinforcing the commitment to individualized cancer care.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Gastrointestinal Stromal Tumor Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Targeted Therapy
- Chemotherapy
- Immunotherapy
- Surgery
- Radiation Therapy
- Others
Global Gastrointestinal Stromal Tumor Market Size by Drug Type & CAGR (2026-2033)
- Market Overview
- Tyrosine Kinase Inhibitors (TKIs)
- Immune Checkpoint Inhibitors
- Cytotoxic Chemotherapy Agents
- Others
Global Gastrointestinal Stromal Tumor Market Size by Disease Stage & CAGR (2026-2033)
- Market Overview
- Localized Gastrointestinal Stromal Tumor (GIST)
- Locally Advanced Gastrointestinal Stromal Tumor (GIST)
- Metastatic Gastrointestinal Stromal Tumor (GIST)
- Recurrent Gastrointestinal Stromal Tumor (GIST)
Global Gastrointestinal Stromal Tumor Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Injectable
Global Gastrointestinal Stromal Tumor Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Gastrointestinal Stromal Tumor Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Cancer Centers
- Ambulatory Surgical Centers
- Academic & Research Institutes
Global Gastrointestinal Stromal Tumor Market Size & CAGR (2026-2033)
- North America (Treatment Type, Drug Type, Disease Stage, Route of Administration, Distribution Channel, End User)
- US
- Canada
- Europe (Treatment Type, Drug Type, Disease Stage, Route of Administration, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment Type, Drug Type, Disease Stage, Route of Administration, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment Type, Drug Type, Disease Stage, Route of Administration, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment Type, Drug Type, Disease Stage, Route of Administration, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Blueprint Medicines Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Deciphera Pharmaceuticals Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
